Modeling early treatment response in AML from cell-free tumor DNA

Monitoring disease response after intensive chemotherapy for acute myeloid leukemia (AML) currently requires invasive bone marrow biopsies, imposing a significant burden on patients. In contrast, cell-free tumor DNA (ctDNA) in peripheral blood, carrying tumor-specific mutations, offers a less-invasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dantong, Rausch, Christian, Buerger, Simon A., Tschuri, Sebastian, Rothenberg-Thurley, Maja, Schulz, Melanie, Hasenauer, Jan, Ziemann, Frank, Metzeler, Klaus H., Marr, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690559/
https://www.ncbi.nlm.nih.gov/pubmed/38047080
http://dx.doi.org/10.1016/j.isci.2023.108271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690559/
https://www.ncbi.nlm.nih.gov/pubmed/38047080
http://dx.doi.org/10.1016/j.isci.2023.108271

Ejemplares similares